Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on April 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 2, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sales were executed under a 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $8.8182, with individual sales prices ranging from $8.71 to $8.98 per share.
• Following the transaction, Borgeson directly owns 7,241,308 shares of Recursion Pharmaceuticals.
• The reporting person has provided full sale price information for each lot to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares by a company director under a pre-existing trading plan.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of insider trading. The market typically analyzes these sales in the context of the company's overall performance and future prospects.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in investor confidence, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates